×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IRWD – ironwood pharmaceuticals, inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IRWD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
07:25 am
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Craig Hallum from a "hold" rating to a "strong-buy" rating.
Medium
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Craig Hallum from a "hold" rating to a "strong-buy" rating.
1/5
01:48 pm
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $3.00 to $5.00. They now have an "equal weight" rating on the stock.
Low
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $3.00 to $5.00. They now have an "equal weight" rating on the stock.
1/5
08:33 am
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "market outperform" rating. They now have a $8.00 price target on the stock.
Low
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "market outperform" rating. They now have a $8.00 price target on the stock.
1/5
06:01 am
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.
1/3
05:42 am
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Medium
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
1/2
09:39 am
irwd
Ironwood Pharmaceuticals Projects Higher 2026 US Sales for Irritable Bowel Syndrome With Constipation Drug [Yahoo! Finance]
High
Report
Ironwood Pharmaceuticals Projects Higher 2026 US Sales for Irritable Bowel Syndrome With Constipation Drug [Yahoo! Finance]
1/2
07:05 am
irwd
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
High
Report
Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance
12/16
04:38 pm
irwd
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Ironwood Pharmaceuticals (NASDAQ:IRWD) had its "sell (d)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
07:05 am
irwd
ironwood pharmaceuticals, inc. - class a
BEAT
Report
17.7%
ironwood pharmaceuticals, inc. - class a
5/7/2025
07:05 am
irwd
ironwood pharmaceuticals, inc. - class a
MISS
Report
-13.0%
ironwood pharmaceuticals, inc. - class a
2/27/2025
07:00 am
irwd
ironwood pharmaceuticals, inc. - class a
MISS
Report
-8.0%
ironwood pharmaceuticals, inc. - class a
2/27/2025
07:00 am
irwd
ironwood pharmaceuticals, inc. - class a
MISS
Report
-12.4%
ironwood pharmaceuticals, inc. - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/7
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Jan 05 Filed by: Silver Ronald
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Jan 05 Filed by: Silver Ronald
1/5
04:42 pm
irwd
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Silver Ronald
Medium
Report
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Silver Ronald
1/2
07:06 am
irwd
Form 8-K IRONWOOD PHARMACEUTICALS For: Jan 02
High
Report
Form 8-K IRONWOOD PHARMACEUTICALS For: Jan 02
12/23
07:06 am
irwd
Form 8-K IRONWOOD PHARMACEUTICALS For: Dec 18
Medium
Report
Form 8-K IRONWOOD PHARMACEUTICALS For: Dec 18
12/17
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Dec 15 Filed by: DENNER ALEXANDER J
Medium
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Dec 15 Filed by: DENNER ALEXANDER J
11/26
07:00 am
irwd
Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 25
High
Report
Form 8-K IRONWOOD PHARMACEUTICALS For: Nov 25
11/19
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 17 Filed by: Gaskins Tammi L
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Nov 17 Filed by: Gaskins Tammi L
11/14
04:08 pm
irwd
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Gaskins Tammi L
Low
Report
Form 144 IRONWOOD PHARMACEUTICALS Filed by: Gaskins Tammi L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/16
Form SC 13D IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP
11.5%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
TOP News Decliners
3/17
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: Dreyfus Andrew
-10.8%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: